Johnson & Johnson today announced that the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee unanimously voted to recommend Emergency Use Authorization for the Company's single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by ...